Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft

Anna Riccardi, Daniela Meco, Paolo Ubezio, Giorgio Mazzarella, Mirko Marabese, Glynn T. Faircloth, José Jimeno, Maurizio D'Incalci, Riccardo Riccardi

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Our objective was to evaluate in vitro and in vivo the effect of the combination of trabectedin (Yondelis, ET-743) and irinotecan (CPT-11) or its major metabolite SN-38 in a human rhabdomyosarcoma cell line. The schedule trabectedin (1 h) followed by irinotecan or SN-38 (24 h) and the opposite sequence (irinotecan or SN-38 24 h followed by trabectedin 1 h) were analyzed in a rhabdomyosarcoma cell line. In vivo studies were conducted with trabectedin and irinotecan at the doses of 0.2 and 20 mg/kg, respectively, simultaneously administered with a q4d × 3 schedule. In vitro studies indicated an overall additive effect [combination index (CI) relatively close to 1.0], with the former schedule slightly superior to the latter (at the IC50 effect levels: CI = 0.89 versus 1.07). Neither transcription nor expression of DNA topoisomerase I was affected by trabectedin treatment. In vivo the therapeutic results of the combination were certainly more impressive: trabectedin and irinotecan combination caused a strong and long-lasting effect on tumor growth (tumor volume inhibition = 89%, log10 cell kill = 1.6), whereas each drug given as a single agent was only marginally active. The discrepancy between the in vitro and in vivo results suggests possible mechanisms involving host cells, other than tumor cells. The striking effects of the combination observed in vivo could be related to a combination of a direct cytotoxic and an anti-inflammatory indirect effect. The very marked and long-lasting effect of the trabectedin and irinotecan combination in vivo suggests a basis for a clinical evaluation in pediatric patients with rhabdomyosarcoma.

Original languageEnglish
Pages (from-to)811-815
Number of pages5
JournalAnti-Cancer Drugs
Volume16
Issue number8
DOIs
Publication statusPublished - Sep 2005

Fingerprint

trabectedin
irinotecan
Rhabdomyosarcoma
Heterografts
Appointments and Schedules
Cell Line
Type I DNA Topoisomerase

Keywords

  • Drug combination
  • Irinotecan
  • Rhabdomyosarcoma
  • SN-38
  • Trabectedin

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research
  • Oncology

Cite this

Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft. / Riccardi, Anna; Meco, Daniela; Ubezio, Paolo; Mazzarella, Giorgio; Marabese, Mirko; Faircloth, Glynn T.; Jimeno, José; D'Incalci, Maurizio; Riccardi, Riccardo.

In: Anti-Cancer Drugs, Vol. 16, No. 8, 09.2005, p. 811-815.

Research output: Contribution to journalArticle

Riccardi, Anna ; Meco, Daniela ; Ubezio, Paolo ; Mazzarella, Giorgio ; Marabese, Mirko ; Faircloth, Glynn T. ; Jimeno, José ; D'Incalci, Maurizio ; Riccardi, Riccardo. / Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft. In: Anti-Cancer Drugs. 2005 ; Vol. 16, No. 8. pp. 811-815.
@article{3186e45726b645c6b394c4b55e3602dd,
title = "Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft",
abstract = "Our objective was to evaluate in vitro and in vivo the effect of the combination of trabectedin (Yondelis, ET-743) and irinotecan (CPT-11) or its major metabolite SN-38 in a human rhabdomyosarcoma cell line. The schedule trabectedin (1 h) followed by irinotecan or SN-38 (24 h) and the opposite sequence (irinotecan or SN-38 24 h followed by trabectedin 1 h) were analyzed in a rhabdomyosarcoma cell line. In vivo studies were conducted with trabectedin and irinotecan at the doses of 0.2 and 20 mg/kg, respectively, simultaneously administered with a q4d × 3 schedule. In vitro studies indicated an overall additive effect [combination index (CI) relatively close to 1.0], with the former schedule slightly superior to the latter (at the IC50 effect levels: CI = 0.89 versus 1.07). Neither transcription nor expression of DNA topoisomerase I was affected by trabectedin treatment. In vivo the therapeutic results of the combination were certainly more impressive: trabectedin and irinotecan combination caused a strong and long-lasting effect on tumor growth (tumor volume inhibition = 89{\%}, log10 cell kill = 1.6), whereas each drug given as a single agent was only marginally active. The discrepancy between the in vitro and in vivo results suggests possible mechanisms involving host cells, other than tumor cells. The striking effects of the combination observed in vivo could be related to a combination of a direct cytotoxic and an anti-inflammatory indirect effect. The very marked and long-lasting effect of the trabectedin and irinotecan combination in vivo suggests a basis for a clinical evaluation in pediatric patients with rhabdomyosarcoma.",
keywords = "Drug combination, Irinotecan, Rhabdomyosarcoma, SN-38, Trabectedin",
author = "Anna Riccardi and Daniela Meco and Paolo Ubezio and Giorgio Mazzarella and Mirko Marabese and Faircloth, {Glynn T.} and Jos{\'e} Jimeno and Maurizio D'Incalci and Riccardo Riccardi",
year = "2005",
month = "9",
doi = "10.1097/01.cad.0000172837.67766.6a",
language = "English",
volume = "16",
pages = "811--815",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft

AU - Riccardi, Anna

AU - Meco, Daniela

AU - Ubezio, Paolo

AU - Mazzarella, Giorgio

AU - Marabese, Mirko

AU - Faircloth, Glynn T.

AU - Jimeno, José

AU - D'Incalci, Maurizio

AU - Riccardi, Riccardo

PY - 2005/9

Y1 - 2005/9

N2 - Our objective was to evaluate in vitro and in vivo the effect of the combination of trabectedin (Yondelis, ET-743) and irinotecan (CPT-11) or its major metabolite SN-38 in a human rhabdomyosarcoma cell line. The schedule trabectedin (1 h) followed by irinotecan or SN-38 (24 h) and the opposite sequence (irinotecan or SN-38 24 h followed by trabectedin 1 h) were analyzed in a rhabdomyosarcoma cell line. In vivo studies were conducted with trabectedin and irinotecan at the doses of 0.2 and 20 mg/kg, respectively, simultaneously administered with a q4d × 3 schedule. In vitro studies indicated an overall additive effect [combination index (CI) relatively close to 1.0], with the former schedule slightly superior to the latter (at the IC50 effect levels: CI = 0.89 versus 1.07). Neither transcription nor expression of DNA topoisomerase I was affected by trabectedin treatment. In vivo the therapeutic results of the combination were certainly more impressive: trabectedin and irinotecan combination caused a strong and long-lasting effect on tumor growth (tumor volume inhibition = 89%, log10 cell kill = 1.6), whereas each drug given as a single agent was only marginally active. The discrepancy between the in vitro and in vivo results suggests possible mechanisms involving host cells, other than tumor cells. The striking effects of the combination observed in vivo could be related to a combination of a direct cytotoxic and an anti-inflammatory indirect effect. The very marked and long-lasting effect of the trabectedin and irinotecan combination in vivo suggests a basis for a clinical evaluation in pediatric patients with rhabdomyosarcoma.

AB - Our objective was to evaluate in vitro and in vivo the effect of the combination of trabectedin (Yondelis, ET-743) and irinotecan (CPT-11) or its major metabolite SN-38 in a human rhabdomyosarcoma cell line. The schedule trabectedin (1 h) followed by irinotecan or SN-38 (24 h) and the opposite sequence (irinotecan or SN-38 24 h followed by trabectedin 1 h) were analyzed in a rhabdomyosarcoma cell line. In vivo studies were conducted with trabectedin and irinotecan at the doses of 0.2 and 20 mg/kg, respectively, simultaneously administered with a q4d × 3 schedule. In vitro studies indicated an overall additive effect [combination index (CI) relatively close to 1.0], with the former schedule slightly superior to the latter (at the IC50 effect levels: CI = 0.89 versus 1.07). Neither transcription nor expression of DNA topoisomerase I was affected by trabectedin treatment. In vivo the therapeutic results of the combination were certainly more impressive: trabectedin and irinotecan combination caused a strong and long-lasting effect on tumor growth (tumor volume inhibition = 89%, log10 cell kill = 1.6), whereas each drug given as a single agent was only marginally active. The discrepancy between the in vitro and in vivo results suggests possible mechanisms involving host cells, other than tumor cells. The striking effects of the combination observed in vivo could be related to a combination of a direct cytotoxic and an anti-inflammatory indirect effect. The very marked and long-lasting effect of the trabectedin and irinotecan combination in vivo suggests a basis for a clinical evaluation in pediatric patients with rhabdomyosarcoma.

KW - Drug combination

KW - Irinotecan

KW - Rhabdomyosarcoma

KW - SN-38

KW - Trabectedin

UR - http://www.scopus.com/inward/record.url?scp=24044480041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24044480041&partnerID=8YFLogxK

U2 - 10.1097/01.cad.0000172837.67766.6a

DO - 10.1097/01.cad.0000172837.67766.6a

M3 - Article

C2 - 16096428

AN - SCOPUS:24044480041

VL - 16

SP - 811

EP - 815

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 8

ER -